Levodopa/carbidopa for childhood amblyopia

Invest Ophthalmol Vis Sci. 1993 Oct;34(11):3090-5.

Abstract

Purpose: To evaluate the efficacy and tolerance of two low doses of levodopa/carbidopa (25/6.25 mg, 50/12.5 mg) and placebo (Tums) in 20 children with amblyopia between the ages of 4 and 14 years.

Methods: A double-masked placebo-controlled randomized 8-hour study was performed during which subjects received one of two doses of levodopa/carbidopa or placebo, combined with occlusion of the dominant eye. Visual acuity was measured at baseline and at 1 and 5 hours after capsule ingestion. Tolerance was assessed by questionnaire and physical examination.

Results: Visual acuity significantly improved by one line, from an overall average of 20/121 to 20/96, in the amblyopic eyes of both groups that received levodopa/carbidopa. Visual acuity did not significantly change in the placebo group. Tolerance was similar among all three groups.

Conclusion: Average dose levels of 0.95/0.24 mg/kg and 1.94/0.49 mg/kg of levodopa/carbidopa were found to be well tolerated and efficacious at temporarily improving visual acuity in amblyopic eyes of children.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Amblyopia / drug therapy*
  • Amblyopia / therapy
  • Carbidopa / administration & dosage*
  • Carbidopa / adverse effects
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Double-Blind Method
  • Drug Therapy, Combination
  • Drug Tolerance
  • Female
  • Humans
  • Levodopa / administration & dosage*
  • Levodopa / adverse effects
  • Male
  • Sensory Deprivation
  • Visual Acuity

Substances

  • Levodopa
  • Carbidopa